Cargando…

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

BACKGROUND: RAS-to-ERK signaling is crucial for the onset and progression of advanced thyroid carcinoma, and blocking ERK dimerization provides a therapeutic benefit in several human carcinomas. Here we analyzed the effects of DEL-22379, a relatively specific ERK dimerization inhibitor, on the activ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaballos, Miguel A., Acuña-Ruiz, Adrián, Morante, Marta, Riesco-Eizaguirre, Garcilaso, Crespo, Piero, Santisteban, Pilar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440884/ https://www.ncbi.nlm.nih.gov/pubmed/36056964 http://dx.doi.org/10.1007/s00018-022-04530-9

Ejemplares similares

ß-catenin signaling is required for RAS-driven thyroid cancer through PI3K activation
por: Sastre-Perona, Ana, et al.
Publicado: (2016)

RAS Subcellular Localization Inversely Regulates Thyroid Tumor Growth and Dissemination
por: García-Ibáñez, Yaiza, et al.
Publicado: (2020)

Impaired microRNA processing by DICER1 downregulation endows thyroid cancer with increased aggressiveness
por: Ramírez-Moya, Julia, et al.
Publicado: (2019)

Identification of an interactome network between lncRNAs and miRNAs in thyroid cancer reveals SPTY2D1-AS1 as a new tumor suppressor
por: Ramírez-Moya, Julia, et al.
Publicado: (2022)

Validation of dynamic risk stratification and impact of BRAF in risk assessment of thyroid cancer, a nation-wide multicenter study
por: Pérez-Fernández, Laura, et al.
Publicado: (2023)

Radio-Iodide Treatment: From Molecular Aspects to the Clinical View
por: De la Vieja, Antonio, et al.
Publicado: (2021)

RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball
por: Herrero, Ana, et al.
Publicado: (2021)

Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis
por: Song, Young Shin, et al.
Publicado: (2017)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
por: Morante, Marta, et al.
Publicado: (2022)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations
por: Lu, Meng-Di, et al.
Publicado: (2022)

Squamous Cell Carcinoma of the Thyroid as a Result of Anaplastic Transformation from BRAF-Positive Papillary Thyroid Cancer
por: Basnet, Alina, et al.
Publicado: (2017)

Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer
por: Nabhan, Fadi, et al.
Publicado: (2021)

Targeting the BRAF Signaling Pathway in CD133(pos) Cancer Stem Cells of Anaplastic Thyroid Carcinoma
por: Bozorg-Ghalati, Farzaneh, et al.
Publicado: (2019)

Genomically Driven Precision Medicine to Improve Outcomes in Anaplastic Thyroid Cancer
por: Pinto, Nicole, et al.
Publicado: (2014)

Anaplastic Transformation of Papillary Thyroid Carcinoma in a Young Man: A Case Study with Immunohistochemical and BRAF Analysis
por: Park, Ji Hye, et al.
Publicado: (2014)

Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
por: Migliorini, Denis, et al.
Publicado: (2017)

Anaplastic Thyroid Carcinoma
por: Taccaliti, Augusto, et al.
Publicado: (2012)

Melatonin synergizes BRAF‐targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling
por: Liao, Yina, et al.
Publicado: (2020)

Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status
por: Ishihara, Sae, et al.
Publicado: (2019)

Inhibitors of BRAF dimers using an allosteric site
por: Cotto-Rios, Xiomaris M., et al.
Publicado: (2020)

SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics
por: Boned del Río, Isabel, et al.
Publicado: (2019)

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
por: Janostiak, Radoslav, et al.
Publicado: (2019)

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF(V600E) Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study
por: Zhao, Xiao, et al.
Publicado: (2023)

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
por: Wang, Jennifer R., et al.
Publicado: (2019)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Anaplastic Thyroid Carcinoma: An Update
por: Jannin, Arnaud, et al.
Publicado: (2022)

BRAF V600E protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancers
por: Gao, Yanyan, et al.
Publicado: (2022)

ERK Signals: Scaffolding Scaffolds?
por: Casar, Berta, et al.
Publicado: (2016)

Role of the Wnt Pathway in Thyroid Cancer
por: Sastre-Perona, Ana, et al.
Publicado: (2012)

Interactome dynamics of RAF1-BRAF kinase monomers and dimers
por: Iglesias-Martinez, Luis F., et al.
Publicado: (2023)

Risk Factors for Anaplastic Thyroid Cancer
por: Zivaljevic, V., et al.
Publicado: (2014)

The Role of Tracheostomy in Anaplastic Thyroid Carcinoma
por: Xu, Jia, et al.
Publicado: (2015)

Anaplastic Thyroid Carcinoma with Gastric Metastasis
por: CHAVEZ, A.A.L., et al.
Publicado: (2018)

Treatment Outcomes in Anaplastic Thyroid Cancer
por: Corrigan, Kelsey L., et al.
Publicado: (2019)

Anaplastic Cancer of the Thyroid: The Viper in the Pit
por: Seshadri, Krishna G.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l0at5tshhsdec7bo4ss017vtha